Different origin, different mechanism, one shared theme — tissue repair. BPC-157 is a synthetic pentadecapeptide derived from a protein in gastric juice, stable in stomach acid, acting through VEGFR2-Akt-eNOS and related pathways in tendon, ligament and gut research. TB-500 is the synthetic 17-23 fragment of thymosin beta-4, sequestering actin and driving cell migration.
Key parameters side by side
Parameter
BPC-157
TB-500
Evidence status
Preclinical
Clinical Trial
Sequence length
15
7
Molecular weight
1419.53 Da
889.01 Da
Same for both: Category — Tissue Repair
Frequently asked questions
In origin and in mechanism. BPC-157 is 15 amino acids from a protective gastric protein and works through angiogenic and kinase pathways. TB-500 is the seven-residue 17-23 fragment of thymosin beta-4 (N-acetyl-LKKTETQ) — the molecule the FDA reviewed separately from the full-length peptide — and its effects start from one biochemical event: binding monomeric actin via the LKKTETQ motif.
Our profiles record different evidence stages. BPC-157 is preclinical: three decades of animal and cell work with no regulatory approval anywhere. TB-500 is marked clinical, yet it has no approved indication either, and almost all of the evidence carried under that name belongs to full-length thymosin beta-4 rather than to the fragment.
Tissue Repair
BPC-157
Preclinical
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. First characterized in the 1990s, it is uniquely stable in stomach acid for over 24 hours — a property rare among peptides. Over three decades of preclinical research have demonstrated its healing and protective effects across multiple systems: accelerating tendon, ligament, and muscle repair, protecting the GI tract, promoting angiogenesis, and exerting neuroprotective activity through the VEGFR2-Akt-eNOS, FAK-paxillin, JAK-2/STAT, and ERK1/2 pathways. BPC-157 is not FDA-approved and remains an investigational research compound.
TB-500 is a synthetic, N-acetylated heptapeptide: fragment 17-23 of thymosin beta-4 (Tβ4), which is the actin-binding motif LKKTETQ. That is how the FDA defines it — N-acetyl-LKKTETQ, C38H68N10O14, 889.01 g/mol as the free base and 949.1 as the acetate, UNII QHK6Z47GTG — and calls it the presumed active moiety of full-length Tβ4, a naturally occurring 43-amino acid peptide present in virtually all human and animal cells (Briefing Document for the Pharmacy Compounding Advisory Committee, 23 July 2026).
The same name is also sold on the research-peptide market for full-length synthetic Tβ4 of 43 amino acids, so what a particular product contains is settled by its certificate of analysis, not by its label. The distinction decides what the evidence covers: almost everything published concerns full-length Tβ4 (RGN-259 and related programmes). The fragment keeps actin binding and the cell migration that follows from it, but carries neither the Ac-SDKP domain (residues 1-4, anti-inflammatory and antifibrotic) nor residues 1-15 (anti-apoptotic).
The peptide has generated substantial research interest for its therapeutic potential in wound healing, cardiac repair following myocardial infarction, neurological recovery, and musculoskeletal injury. It is widely used in equine and veterinary medicine for tissue repair. TB-500 is not approved for human clinical use and is prohibited by WADA.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. First characterized in the 1990s, it is uniquely stable in stomach acid for over 24 hours — a property rare among peptides. Over three decades of preclinical research have demonstrated its healing and protective effects across multiple systems: accelerating tendon, ligament, and muscle repair, protecting the GI tract, promoting angiogenesis, and exerting neuroprotective activity through the VEGFR2-Akt-eNOS, FAK-paxillin, JAK-2/STAT, and ERK1/2 pathways. BPC-157 is not FDA-approved and remains an investigational research compound.
TB-500 is a synthetic, N-acetylated heptapeptide: fragment 17-23 of thymosin beta-4 (Tβ4), which is the actin-binding motif LKKTETQ. That is how the FDA defines it — N-acetyl-LKKTETQ, C38H68N10O14, 889.01 g/mol as the free base and 949.1 as the acetate, UNII QHK6Z47GTG — and calls it the presumed active moiety of full-length Tβ4, a naturally occurring 43-amino acid peptide present in virtually all human and animal cells (Briefing Document for the Pharmacy Compounding Advisory Committee, 23 July 2026).
The same name is also sold on the research-peptide market for full-length synthetic Tβ4 of 43 amino acids, so what a particular product contains is settled by its certificate of analysis, not by its label. The distinction decides what the evidence covers: almost everything published concerns full-length Tβ4 (RGN-259 and related programmes). The fragment keeps actin binding and the cell migration that follows from it, but carries neither the Ac-SDKP domain (residues 1-4, anti-inflammatory and antifibrotic) nor residues 1-15 (anti-apoptotic).
The peptide has generated substantial research interest for its therapeutic potential in wound healing, cardiac repair following myocardial infarction, neurological recovery, and musculoskeletal injury. It is widely used in equine and veterinary medicine for tissue repair. TB-500 is not approved for human clinical use and is prohibited by WADA.